1350P Bridging the platforms of adaptive clinical trials in oncology and accelerating clinical research in rare genomic aberrations

Abstract

In the past few years several adaptive, multi-drug, multi-stage, pan-cancer trials have been launched based on the concept of the Drug Rediscovery Protocol (DRUP). These trials independently study the effect of existing medicines on specific genomic aberrations outside their approved label. Because these are rare cancers with uncommon mutations, patient accrual is slow.